Collectively, these results showed that MyD88 deficiency in myeloid cells considerably inhibited the development of diabetes in mice treated with STZ, suggesting that MyD88 signaling in myeloid cells promotes autoimmune responses leading to the development of T1D. Here, MYD88 is linked to type 1 diabetes mellitus.